Provision of Hypertension and Lipids Optimisation Project

This is a notice to inform the market the procurement has been abandoned. NHS Norfolk and Waveney Integrated Care Board sought to procure a Hypertension and Lipids Optimisation Project.

The successful provider staff was expected to work with the ICB Cardiovascular disease team, the N&W Protect NoW team, and General Practice to improve clinical effectiveness through case finding and management of patients. NHS Norfolk and Waveney Integrated Care Board sought to launch a large-scale CVD Prevention project using a Population Health Management approach to case finding and intervention.

The project will focus on hypertension and lipid management, with patients being identified and subsequently risk-stratified using the ICB software. The ABCDE program aims to improve the care of patients at risk of Cardiovascular events through case finding and improved management of high-risk individuals.

This project is considered a system priority to see our population lead healthier, longer lives, whilst simultaneously reducing pressures on the health system through early detection and management. The successful provider is was expected to supply and manage Clinical Prescribers who will liaise with the ICB Protect NoW team, General Practice, and patients.

A personalised care approach will be used to support pharmacological and social prescribing for our patient cohort. Prescribers must be able to initiate relevant medicines.

Prescribers must initiate medicines in line with N&W criteria. Patients will be identified using the ICB’s population health management software (Eclipse).

Patients identified as eligible for medication will be consented by Protect NoW and subsequently made available to the provider, and the prescribers are to systematically contact this patient cohort and seek to initiate and / or optimise treatment in line with ICB and national guidance. The provider will be expected to liaise with the relevant Practice where required on necessary ongoing management and monitoring.

This is a notice to inform the market the procurement has been abandoned. NHS Norfolk and Waveney Integrated Care Board sought to procure a Hypertension and Lipids Optimisation Project.

The successful provider staff will be expected to work with the ICB Cardiovascular disease team, the N&W Protect NoW team, and General Practice to improve clinical effectiveness through case finding and management of patients. This was a 1 year contract with the option to extend for up to an additional 2 years.

The 1 year contract value is a a maximum of £200,000. Any additional extensions are estimated to be £200,000 per annum a maximum contract value of £600,000 over the full 3 year contract period.

Service Description: NHS Norfolk and Waveney Integrated Care Board sought to launch a large-scale CVD Prevention project using a Population Health Management approach to case finding and intervention.

The project will focus on hypertension and lipid management, with patients being identified and subsequently risk-stratified using the ICB software. The ABCDE program aims to improve the care of patients at risk of Cardiovascular events through case finding and improved management of high-risk individuals.

This project is considered a system priority to see our population lead healthier, longer lives, whilst simultaneously reducing pressures on the health system through early detection and management. The successful provider was expected to supply and manage Clinical Prescribers who will liaise with the ICB Protect NoW team, General Practice, and patients.

A personalised care approach will be used to support pharmacological and social prescribing for our patient cohort. Prescribers must be able to initiate relevant medicines.

Prescribers must initiate medicines in line with N&W criteria. Patients will be identified using the ICB’s population health management software (Eclipse).

The ICB Protect NoW Team will contact patients via digital (and print, if necessary) mediums to inform them of their relative risks and changes they can make in their lifestyles and diets and to encourage medication adherence where necessary. Patients identified as eligible for medication will be consented by Protect NoW and subsequently made available to the provider, and the prescribers are to systematically contact this patient cohort and seek to initiate and / or optimise treatment in line with ICB and national guidance. The provider will be expected to liaise with the relevant Practice where required on necessary ongoing management and monitoring.